Abpro Holdings (ABPO) Receivables - Other (2022 - 2026)
Abpro Holdings' (ABPO) quarterly Receivables - Other came in at $890000.0 in Q1 2026, up 10.42% YoY from $806000.0 in Q1 2025, and up 2.42% on a QoQ basis from $869000.0 in Q4 2025.
Abpro Holdings (ABPO) Receivables - Other (2022 - 2026) Analysis & Trends
Abpro Holdings (ABPO) has 5 years of Receivables - Other data on file, last reported at $890000.0 in Q1 2026.
- Quarterly Receivables - Other rose 10.42% year-over-year to $890000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $890000.0 (up 10.42% YoY) and the FY2025 annual result came in at $869000.0, up 10.7% from the prior year.
- Receivables - Other advanced to $890000.0 in Q1 2026, from $869000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $3.5 million in Q1 2022 to a low of $103000.0 in Q3 2024.
- A 5-year average of $1.0 million and a median of $827000.0 in 2025 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2024 — Receivables - Other advanced 4.53% — and 2025, when it jumped 723.3%.
- Tracing ABPO's Receivables - Other over 5 years: stood at $3.5 million in 2022, then tumbled by 78.54% to $751000.0 in 2023, then grew by 4.53% to $785000.0 in 2024, then grew by 10.7% to $869000.0 in 2025, then climbed by 2.42% to $890000.0 in 2026.
- The last three Receivables - Other figures came in at $890000.0 (Q1 2026), $869000.0 (Q4 2025), and $848000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Abpro Holdings | 1.14 Mn | 1.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 890,000.00 |
| Mar 31, 2026 | 890,000.00 |
| Dec 31, 2025 | 869,000.00 |
| Dec 31, 2025 | 869,000.00 |
| Sep 30, 2025 | 848,000.00 |
| Sep 30, 2025 | 848,000.00 |
| Jun 30, 2025 | 827,000.00 |
| Jun 30, 2025 | 827,000.00 |
| Mar 31, 2025 | 806,000.00 |
| Mar 31, 2025 | 806,000.00 |
| Dec 31, 2024 | 785,000.00 |
| Dec 31, 2024 | 785,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Dec 31, 2023 | 751,000.00 |
| Dec 31, 2023 | 751,000.00 |
| Mar 31, 2022 | 3.50 Mn |
| Mar 31, 2022 | 3.50 Mn |